ARTRYA®
Coronary Artery Disease.
We see you.

2026 Annual General Meeting - Details of Webinar

PERTH, Australia, 6 November 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, reminds shareholders that the Annual General Meeting (**AGM**) of the Company will be held on **Friday 13 November 2026 at 11.30am AWST**.

The AGM will be held at Artrya's offices at 1257 Hay Street, West Perth, Western Australia.

2026 AGM Webinar details

Artrya invites any shareholder unable to attend AGM in person, to register to view a Webinar of the AGM as set out below. The Webinar will not be interactive, Shareholders attending will be in a listen only mode and will be unable to cast their vote on any resolution or to raise a question.

Date: Friday 13 November 2026

Time: 11.30am AWST (2.30pm AEDT)

To pre-register to attend this 2026 AGM Webinar, please use the link below:

https://artrya.zoom.us/webinar/register/WN_0_KcKQ74SVG2ajyvWdIBFQ

If Shareholders have questions, they should be submitted in writing prior to **11:30am (AWST) on Wednesday, 11 November 2026** on **investors@artrya.com**.

- Ends -

This ASX Announcement is authorised for release by the Company Secretary of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through Innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit **www.artrya.com** or follow us on LinkedIn at **www.linkedin.com/company/artrya**

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com